Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

Crohn's Disease Clinical Trial

Official title:

Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00300118
• Other study ID #: BUC-52/CDA
• Secondary ID: 2004-001213-34
• Status: Completed
• Phase: Phase 3
• First received: March 7, 2006
• Last updated: May 16, 2014
• Start date: September 2004
• Est. completion date: May 2008

Study information

• Verified date: May 2014
• Source: Dr. Falk Pharma GmbH
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.

Description:

Crohn's disease is often treated with glucocorticoids or mesalazine. Both drugs are indicated for active Crohn's disease. Treatment with mesalazine is indicated for the treatment of mildly to moderately active Crohn's disease. Budesonide 9 mg/day or mesalazine 4.5 g/day are better than lower doses.

So far only one trial compares the efficacy and safety of budesonide and 5-ASA. The result of this trial is that budesonide is more effective in inducing remission than mesalazine. The primary objective of this trial is to confirm this result for other presentations of budesonide and mesalazine; i.e. Budenofalk® capsules (9 mg/day) and Salofalk® tablets (Eudragit-L-coated oral mesalazine; 4.5 g/day) in moderately active Crohn's disease. Mesalazine is used in this trial as a comparator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 311
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria (main):

• Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g. pain localization, pain intensity, blood in stool) and behaviour (according to Vienna classification) should be unchanged compared to former episodes]

• Localisation of CD either in terminal ileum, ascending colon or ileocolitis

• Active phase of disease (200 < CDAI < 400)

Exclusion Criteria (main):

• Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with present symptoms

• CD in the rectum currently present

• Short bowel syndrome

• Septic complications

• Baseline stool positive for germs causing bowel disease

• Abscess, perforation or active fistulas

• Ileostomy or colostomy

• Resection of more than 50 cm of the ileum

• Bowel surgery within the last 3 months

• Immediate surgery required

• Clinical signs of stricturing disease

• Subileus within the last 6 months

• Suspicion of ileus, subileus or corresponding symptomatology

• Contra-indications, special warnings and precautions mentioned in SmPC

• Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study

• Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last month before baseline visit

• Treatment with anti-TNF-a therapy within 6 months before baseline visit

• Conventional steroids (iv, po, rectal) within 2 weeks before the study

• > 6 mg/d budesonide po or > 3 g/d mesalazine po within 2 weeks before the study

• Patients known to be steroid-refractory or steroid-dependent from former CD episodes

• Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last 2 weeks

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Drug:
• budesonide
9 mg
• mesalazine
4.5 g

Locations

Country	Name	City	State
Germany	Ev. Krankenhaus Hattingen GmbH	Hattingen

Sponsors (1)

Lead Sponsor	Collaborator
Dr. Falk Pharma GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Tromm A, Bunganic I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Buden — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of remission
Secondary	Response to treatment
Secondary	Time to response
Secondary	Time to remission
Secondary	PGA
Secondary	QoL